TOBACCO Theater - Amsterdam, Netherlands

Thursday, September 27th 2018

Join international experts and guest speakers from industry and academia at the historic TOBACCO Theater in the heart of Amsterdam to learn about relevant topics and recent case studies in particle-based pharmaceutical products. The extended agenda will allow time for expert discussion, idea exchange and networking.  Please come and enjoy a welcome reception the evening of Wednesday, September 26th including cocktails, hors d'oeuvres and networking! Be sure to stay afterwards for a celebration upon an evening canal cruise featuring the sights of Amsterdam’s UNESCO-listed canals, cocktails and interesting facts about the city.

Sponsored by: Lubrizol LifeSciences, Particle Sciences, Inc., and Corbion

Registration Now Open!

Seating is limited, so sign up now to reserve your spot for this exclusive event.

Register Here

About the Seminar

Seminar

The Seminar

  • Find new business opportunities
  • Increase the bioavailability of a drug
  • Control the release of a drug
  • Increase the site specificity of delivery
  • Stabilize labile molecules from degradation
Learnings

The Learnings

Particle-based formulation considerations:

  • Potential actives
  • Excipients used
  • Methods of manufacturing
  • Characterisation
  • Regulatory landscape
Audience

The Audience

  • Researchers, Scientists & Biotechnology Experts
  • Branded & Generic Pharmaceutical Companies
  • Biotechnology Companies

Topics

  • Nanoparticles in Pharma
  • Microparticles in Pharma
  • Characterisation & Analysis of Particulate Based Systems    

  • PLGA - Considerations for Drug Delivery
  • Regulatory Perspectives
  • Academic Perspectives

View the complete agenda.

Registration Now Open!

Seating is limited, so sign up now to reserve your spot for this exclusive event.

Register Here

Location

The Speakers

Andrew Loxley

Andrew Loxley

Dr. Loxley is an international consultant and entrepreneur with twenty-five years experience in the development of products based on nano-particles, micro-particles and polymers. He has held senior leadership positions at a number of companies, and created value for a number of start-ups leading to exits totaling more than $1.5 BN. At Particle Sciences, part of Lubrizol LifeSciences, the premier Pharmaceutical Formulation CDMO in the USA, Dr. Loxley led the development of numerous novel formulations based on liposomes, lipid and polymer nano- and micro- particles, bio-resorbable and bio-degradable polymers, and polymer drug-eluting devices, using techniques including nano-milling, microfluidization, spray drying, melt-chill, hot-melt extrusion and injection molding. A passionate and engaging educator, Dr Loxley has been invited to share his experience and insights by Ivy League Universities, international conferences, and a host of private companies. He has authored several journal articles, magazine features and technical briefs, contributed to books on nano-formulations and drug-eluting devices and is a named inventor on more than forty patents. Dr. Loxley earned his PhD in Physical Chemistry at the University of Bristol, UK, focused on particle engineering.

Michiel van Alst

Michiel van Alst

Mr. Michiel van Alst leads the New Business Development and Marketing department within the Biomaterials business unit at Corbion.   Corbion Biomaterials supplies a proven family of resorbable polymers under the brand name of PURASORB® including Poly (DL-lactide), Poly (L-lactide), Polyglycolide, poly (DL-lactide / Glycolide) copolymers and Polycaprolactone.  Michiel’s work focuses on Drug Delivery and delivered multiple presentations on the subject and contributed to several articles focused on the utilization and commercialization of resorbable polymers. Prior to his current position, Michiel was involved in various positions in Sales and Research & Development, totaling up to 15 years of experience with resorbable polymers utilized in pharmaceutical markets. Preceding Corbion, Michiel held a position at a contract research organization performing project related to numerous biodegradable polymers. Michiel received his MSc in the field of Chemical Engineering and Polymer Technology from the Eindhoven University.  

Wim E. Hennink

Wim E. Hennink

Wim Hennink is head of the Department of Pharmaceutics and an expert in the design and application of biodegradable polymers for pharmaceutical and biomedical purposes. Wim Hennink obtained his Ph.D. degree in 1985 at Twente University of Technology with a thesis on biomaterials research. From 1985 until 1992 he held various positions within the industry. In 1992 he was appointed professor of Pharmacy at the University of Utrecht. From 1996 until present he has been head of the Pharmaceutics division. His main research interests are in the field of polymeric drug delivery systems. He has published over 520 papers, chapters and holdes 20 patents. Hennink’s team has made major contributions to the development of polymeric micelles for targeted delivery of anti-cancer drugs. An efficient core-crosslinked system has been developed that will now undergo clinical evaluation by a spin-off company (Cristal Therapeutics).

Dr. Leo  G.J. de Leede

Dr. Leo G.J. de Leede

Dr. de Leede (Pharm. D.) obtained his Ph.D. degree at Leiden University in 1983 and specialized in pharmacokinetics, biopharmaceutics and complex dosage forms. At Organon he was the co-inventor of several innovative pharmaceutical products based on polymeric devices. He was active in various functions within Gist-brocades, Yamanouchi Europe (currently Astellas) and Octoplus developing pharmaceutical products. These products were either complex active agent formulations or innovative dosage forms such as microspheres, liposomes or polymeric devices. He took the initiative to establish Uniphar, a large network collaboration on drug targeting between the Universities of Leiden, Utrecht and Groningen with Yamanouchi. In 2009 he started Exelion Bio-Pharmaceutical Consultancy and advices pharmaceutical companies in their drug development strategy and plans for complex and innovative dosage forms.